Loading clinical trials...

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab. | Clinical Trials | Clareo Health

TERMINATEDPhase 4NCT04381494

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

A study of whether mobile devices can improve the detection of pulmonary AEs (including pneumonitis) in stage III NSCLC patients post-CRT, while on durvalumab.

Lead sponsor: AstraZeneca•18 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Related studies

UNKNOWN

Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC

NCT04161352 · Unresectable Stage III NSCLC

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 22, 2023Terms

Trial snapshot

StatusTERMINATED

PhasePHASE4

Enrollment40

Start dateApr 2020

Last updatedJun 22, 2023

Condition

Unresectable Stage III NSCLC

Locations shown

Research Site

Long Beach, California

Research Site

Santa Ana, California

Research Site

Englewood, Colorado

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 22, 2023Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC

Trial snapshot

Condition

Locations shown

For caregivers